Trevi Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Trevi Therapeutics initiated Phase 3 OCEAN-1 trial for IPF-related chronic cough in Q2 2026, with Phase 3 OCEAN-2 expected Q3 2026 and topline data in H1 2028 and H2 2027 respectively. Company completed $162.3M equity offering in April 2026, ending Q2 with $318.9M cash/securities (54% of market cap), extending runway to 2030. Q2 R&D expenses rose to $15.2M (+61% YoY), net loss was $17.8M ($12.3M YoY).
Why this rating
Multiple Phase 3 initiations represent material clinical progress toward potential first-in-class therapy in large unmet-need markets (~140K IPF, ~228K non-IPF ILD, ~2-3M RCC patients). Strong cash position supports multi-year trial execution. Balanced against clinical-stage risk and higher burn rate.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.